Stelara Reduces Risk of Hospitalization, Surgery for Crohn’s Patients, New Phase 3 Data Show

Stelara Reduces Risk of Hospitalization, Surgery for Crohn’s Patients, New Phase 3 Data Show
Stelara (ustekinumab) can reduce the risk of Crohn’s disease-related hospitalization and surgery, according to new two-year Phase 3 results announced by Janssen, the therapy’s maker. This new analysis of long-term data from the ongoing Phase 3 IM-UNITI extension trial (NCT01369355) was presented at the 2018 Digestive Disease Week meeting, recently held in Washington, D.C. The abstract was

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *